Your shopping cart is currently empty

Vedaprofen (PM 150) inhibits COX-1 and reduces prostaglandin H2 synthesis with anti-inflammatory activities. Vedaprofen is an inhibitor of Escherichia coli sliding clamp with the IC50 of 222 μM and Ki of 131 μM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $49 | In Stock | In Stock | |
| 5 mg | $67 | In Stock | In Stock | |
| 10 mg | $118 | In Stock | In Stock | |
| 25 mg | $238 | In Stock | In Stock | |
| 50 mg | $353 | In Stock | In Stock | |
| 100 mg | $495 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $101 | In Stock | In Stock |
| Description | Vedaprofen (PM 150) inhibits COX-1 and reduces prostaglandin H2 synthesis with anti-inflammatory activities. Vedaprofen is an inhibitor of Escherichia coli sliding clamp with the IC50 of 222 μM and Ki of 131 μM. |
| In vitro | Vedaprofen blocks the activity of the E. coli DNA polymerase III β subunit, preventing DNA replication and repair[1]. Vedaprofen inhibits horse serum TxB2 and horse exudate PGE2 with IC50s of 9 ng/mL and 630 ng/mL, respectively[3]. |
| In vivo | In beagle dogs, the absorption of Vedaprofen (0.5 mg/kg; oral) was rapid (tmax 0.63 h) and almost complete (bioavailability 86%). The terminal half-lives after intravenous and oral administration, 16.8 and 12.7 h respectively, were of the same order of magnitude. Vedaprofen does not accumulate in plasma[2]. |
| Synonyms | Quadrisol, PM 150, CERM 10202 |
| Molecular Weight | 282.38 |
| Formula | C19H22O2 |
| Cas No. | 71109-09-6 |
| Smiles | CC(C(O)=O)c1ccc(C2CCCCC2)c2ccccc12 |
| Relative Density. | 1.132 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 10 mg/mL (35.41 mM), Sonication is recommended. DMF: 25 mg/mL (88.53 mM), Sonication is recommended. DMSO: 50 mg/mL (177.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.08 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||||||||||||
Ethanol/DMF/DMSO
DMF/DMSO
DMSO
| ||||||||||||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.